

# SPHHP Research Activities Newsletter

University at Buffalo


February 2020

## IN THE NEWS

### Congratulations to the Following Awardees!



**Jo Freudenheim**, UB Distinguished Professor and Chair of Epidemiology & Environmental Health, is PI on a continuation award from the Peter T. Rowley Breast Cancer Scientific Research Projects/NYS Dept. of Health for the project entitled, *The Microbiome in the Etiology and Prevention of Breast Cancer*. The project is studying the microbiome in breast tissues, saliva and feces from 100 women with breast cancer to determine whether there are consistent differences by breast cancer subtype and by stage of disease.



**David Hostler**, Professor and Chair of Exercise and Nutrition Sciences, is PI on a new award from Triton Systems, Inc./Dept. of the Navy for the project entitled, *Dive Helmet Communication System*. Divers will be submerged in UB's Center for Research in Special Environment's hyperbaric chamber, which will simulate a depth of at least 60 feet of seawater and background noise to simulate the operational environment. The divers will then provide feedback on the communication intelligibility and general usability of dive helmets.



**Chang-Xing Ma**, Associate Professor of UBiostatistics, is Co-I on a continuation award (PIs: John Canty & James Fallavollita, Medicine) from the National Heart, Lung, Blood Institute/NIH for the project entitled, *PAREPET II\_Prediction of ARrhythmic Events with Positron Emission Tomography II*. The study is collecting preliminary data for a prospective trial to test whether primary prevention implantable cardiac defibrillators can be safely withheld in subjects predicted to be at very low risk of sudden cardiac arrest.



**Jennifer Temple**, Associate Professor of Exercise & Nutrition Sciences, is PI on a continuation award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH for the project entitled, *Sensitization of the Reinforcing Value of Food as a Predictor of Weight Change in Adolescents*. The project is studying weight-related consequences of sensitization to the reinforcing value of food and identify factors that moderate changes in body weight over time as they relate to the reinforcing value of food.

**UB successfully renewed its CTSA Award from the National Center for Advancing Translational Sciences for the project entitled, *University at Buffalo Clinical and Translational Science Institute*.** The following SPHHP faculty are Co-Investigators (PI: Timothy Murphy, Medicine) on two of the Cores:



Members of the Biostatistics, Epidemiology and Research Design (BERD) Core include: **Michael LaMonte**, Research Associate Professor of Epidemiology & Environmental Health, **Jeffrey Miecznikowski**, Associate Professor of Biostatistics (BIO), **Gregory Wilding**, Professor and Chair of BIO and Director of BERD, **Guan Yu**, Assistant Professor of BIO, and **Jiwei Zhao**, Assistant Professor of BIO. The BERD Core offers a range of educational and training opportunities that are responsive to the needs and schedules of faculty, trainees and research staff.



### Inside this issue:

In the News	1-2
Grant Clinic	2-3
NIH Funding Limited	3-4
RFA	4-7
PAR	7
Admin. Comm. Living	8
Foundations: American Cancer Soc.	8
Individual Actions of Sustainability	8



Members of the Team Science Core (TSC) include **Ekaterina Noyes**, Professor of Epidemiology & Environmental Health, Director of the TSC, and **Patricia Ohtake**, Associate Professor of Rehabilitation Science, Co-Director of the TSC. The Team Science Core offers assistance in assembling multidisciplinary clinical research teams by promoting a culture of multidisciplinary collaboration and teamwork, creating opportunities for training and coached experiential learning, and creating a system and metric for assessing team effectiveness and productivity.



## GRANT CLINIC

### NIH Notices

#### [NOT-OD-20-068](#)

##### **Notice of Fiscal Policies in Effect for FY 2020**

**Funding Levels:** Non-competing continuation awards will generally be issued at the commitment level indicated on the Notice of Award.

**Ruth L. Kirschstein National Research Service Awards:** stipends will increase approximately 2% for predocs and 4-5% on average for postdocs. The stipend adjustments will be published in a separate notice to be released soon.

**Salary Limits:** The Executive II salary limitation has increased to \$197,300.

#### [NOT-AT-20-008](#)

##### **Notice of Pre-Application Technical Assistance Webinar for RFA-AT-20-003, Emotional Well-Being: High-Priority Research Networks (U24) – clinical trial optional**

NCCIH, NIA, and NICHD will hold a pre-application webinar on [RFA-AT-20-003](#). The webinar will be held Tuesday, **March 17, 2020** from 2:00-3:00 pm EST. The registration link can be found in the NIH notice.

#### [NOT-OD-20-058](#)

##### **Additional Guidance on the NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research**

NIH previously announced two categories of research that are exempt from the required use of a single IRB. NIH has further clarified exceptions to the Revised Common Rule. As of January 20, 2020, studies subject to the Revised Common Rule must use a single IRB as required by the terms and conditions of award. This includes studies that are not subject to NIH sIRB policy – such as domestic, multisite career development (K) and fellowship (F) awards.

#### [NOT-OD-20-060](#)

##### **Update of NIH Continuous Submission Policy: Change in Submission Deadlines and End of Recent Substantial Service Option**

NIH is implementing changes to ensure diverse advisory groups. Reviewers who are currently eligible for continuous submission through Recent Substantial Service will remain eligible through the end of their term on September 30, 2020. Reviewers who earn eligibility for continuous submission through Recent Substantial Service during the period January 1, 2019, through June 30, 2020, will be eligible from August 1, 2020, through September 30, 2021. Effective February 8, 2020, the continuous submission deadlines for assignment to each council round have been moved back approximately one week. Please refer to the NIH notice for more information on this policy.

#### [NOT-OD-20-061](#)

##### **Updated Guidance on Videos Submitted as NIH Application Materials**

Effective immediately, post-submission videos do not need to be embedded in .pdf files. Acceptable formats for videos are .mp4, .mov, .avi, and .wmv.

### Requests for Information

#### [NOT-DK-20-004](#)

##### **Improved Understanding of Risk and Mechanisms for Developing Obesity in Infants and Young Children**

This RFI seeks innovative ideas to better characterize risk factors and understand the underlying mechanisms through which these factors contribute to the development of obesity during early childhood. The goal is to develop innovative, targeted and more effective strategies for childhood obesity prevention. Please refer to the NIH notice for specific information requested. Responses should be submitted to [NIDDKOOBRES@nih.gov](mailto:NIDDKOOBRES@nih.gov) by **11:59pm on February 28, 2020**

#### [NOT-CA-20-024](#)

##### **Seeking Stakeholder Input on Scientific Gaps and Research Needs to Address Associations between Environmental Exposures and Cancer Risk**

NCI seeks information on scientific gaps related to environmental exposures and cancer risk; scientific gaps that require new resources or approaches; and innovative technologies for exposure assessment and data collection. Responses must be submitted electronically via email to [NCIEnvironmentalExposures@mail.nih.gov](mailto:NCIEnvironmentalExposures@mail.nih.gov). Responses will be accepted until **5:00pm EST on March 1, 2020**.

#### [NOT-OD-20-064](#)

##### **Inviting Comments and Suggestions on a Framework for the NIH-Wide Strategic Plan for FYs 2021-2025**

NIH is currently developing an updated NIH-wide Strategic Plan for FYs 2021-2026 and anticipates releasing it in December 2020. NIH's priority areas include: advancing biomedical and behavioral sciences; developing, maintaining, and renewing scientific research capacity; and exemplifying and promoting the highest level of scientific integrity, public accountability, and social responsibility in the conduct of science. NIH seeks comments on the priority areas, as well as cross-cutting themes (please refer to the NIH notice) and future opportunities or emerging trans-NIH needs. All comments must be submitted electronically on the [submission website](#) by **March 25, 2020, 11:59pm ET**.

#### [NOT-OD-20-059](#)

##### **Scientific Priorities for Behavioral and Social Science Research at NIH**

The Office of Behavioral and Social Sciences Research would like input on the most important or cutting-edge, trans-disease research directions that would accelerate progress in three areas: synergy in basic and applied BSSR; BSSR resources, methods, and measures; and adoption of effective BSSR in practice. Please see the NIH notice for additional information. Responses must be submitted by **March 29, 2020; 11:59pm** at <https://obsr.ideascale.com/>.

### **Notices of Special Interest**

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

#### [NOT-OD-20-055](#) – **Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards**

The overarching goal of this pilot program is to enhance the retention of investigators facing critical life events who are transitioning to the first renewal of their first independent research project grant award or to a second new NIH research project grant award. PD/PIs of the following activity codes are eligible for the program: DP1, DP2, DP5, R01, R00, R15, R21, R35, RF1, and U01. The PD/PI must demonstrate a critical life event such as childbirth or adoption during the parent grant project period; or primary caregiving responsibilities of an ailing spouse, partner, or a member of the immediate family. Supplement requests should be submitted through [PA-18-591](#), and applications must include "NOT-OD-20-055" in box 4b of the SF424. **Expiration Date: March 6, 2023**

#### [NOT-OD-20-032](#) – **The HIV-HCV Substance Use Disorder Syndemic: Therapeutic Approaches**

NIDA is interested in applications that focus on the safety and efficacy of medications to treat the triple comorbidity of HIV/HCV/SUD. Research applications that focus on the following areas are encouraged: development of safe and effective pharmacotherapies; development of non-pharmacological therapies in combination with pharmacotherapies to improve treatment outcome; and Development or improvement in adherence strategies using innovative approaches. This notice applies to due dates on or after June 5, 2020 through Sept. 8, 2023. Applications should be submitted using the parent R01s and NOT-DA-20-032 must be included in box 4B of the SF424 application.

### **Notices of Intent to Publish a Funding Opportunity Announcement**

#### [NOT-EB-20-001](#)

##### **NIBIB Plans to Announce a Prize Competition: NIH Technology Accelerator Challenge: Non-invasive Diagnostic Technologies for Global Health**

This challenge seeks designs for non-invasive technology platforms to diagnose sickle cell disease, malaria, and anemia. Participants will present a design and initial feasibility data or references for a non-invasive diagnostic platform to address two diseases in the vasculature (at least one of which must be sickle cell, malaria, or anemia). Submissions are not being solicited at this time. The challenge announcement will be posted on <https://www.challenge.gov/> and <https://venturewell.org/>. A participant or team will be able to submit an entry for the Challenge by registering at Venturewell.

## **NIH FUNDING OPPORTUNITIES**

### **LIMITED SUBMISSIONS**

Prior approval from UB is required for the following funding opportunities. If you are interested in applying to any of the **limited submissions** listed below, please provide the OVPRED with notification through the [Limited Submissions Mailbox](#) at least 60 days prior to the sponsor's submission deadline before proceeding with an application. As of August 8, 2019, the Limited Submission Program is being managed by Dr. Joseph Balthasar, Executive Director of Research Initiatives, on behalf of the OVPRED. He may be contacted at [jb@buffalo.edu](mailto:jb@buffalo.edu) or by phone at 645-3321 for any questions or advice about the limited submission process.

[RFA-ES-20-006 \(P30\)](#) – clinical trial optional

#### **Environmental Health Sciences Core Centers (EHS CC)**

As intellectual hubs for environmental health science research, the EHS CC is expected to be the thought leaders for the field and advance the goals of the NIEHS Strategic Plan (<http://www.niehs.nih.gov/about/strategicplan/>). The Core Centers provide critical research infrastructure, shared facilities, services and/or resources, to groups of investigators conducting environmental health sciences research. An EHS CC enables researchers to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively. The overall goal of an EHS CC is to identify and capitalize on emerging issues that advance improving the understanding of the relationships among environmental exposures, human biology, and disease. *Only one application allowed per institute.*

**Application Due Date:** May 18, 2020,

[RFA-AI-19-073 \(U01\)](#) – Clinical Research Center (CRC), clinical trial optional

[RFA-AI-19-074 \(UM1\)](#) – Clinical Research Network – Leadership Center (LC), clinical trial required

#### **Childhood Asthma in Urban Settings**

The CRC will conduct both network-wide and site-specific clinical studies and trials with the ultimate goal of developing effective asthma treatment or prevention approaches applicable to children residing in low-income urban settings. The LC will provide the overall scientific strategy and organizational structure to the CAUSE Clinical Research Network and will interact closely with the CRCs to support the conduct of multi-site clinical studies and trials. *Only one application allowed per institute.* **Application Due Date:** June 19, 2020

[PAR-20-106 \(P30\)](#) –clinical trial not allowed

#### **Centers for AIDS Research (CFAR)**

The CFAR program supports research and administrative infrastructure and translational HIV/AIDS research activities at institutions that receive significant HIV/AIDS funding from NIH Institutes or Centers. CFARs are designed to foster synergy and improve coordination of research, support emerging research opportunities, and promote efficiencies through resources shared by multiple independent laboratories. CFARs are intended to promote NIH HIV/AIDS research efforts at CFAR institution(s). *Only one application per institution is allowed.* **Application Due Date:** July 28, 2020

[PAR-20-107 \(P30\)](#) - clinical trial not allowed

#### **Developmental Centers for AIDS Research (D-CFAR)**

The purpose of this program is to provide core facilities, expertise, resources, and services not readily obtained through more traditional funding mechanisms. D-CFAR's provide support to investigators in the development of a competitive standard CFAR. The Centers will allow applicants to develop collaborations, experiment with Core facilities, and to build and strengthen any deficiencies that might adversely affect an application for a standard CFAR award. *Only one application per institution is allowed.* **Application Due Date:** July 28, 2020

## REQUESTS FOR APPLICATIONS (RFA)

### March Due Dates

[RFA-AA-20-006 \(R01\)](#) – clinical trial optional

#### **Impact of Alcohol on the Onset and Progression of Alzheimers Disease and Its Related Dementias**

NIAAA and NIA solicit research projects that combine diverse expertise and use innovative approaches to investigate mechanisms by which alcohol affects brain aging processes to produce dementias and influences development of Alzheimer's disease. This FOA strongly encourages collaborations between alcohol researchers and experts in Alzheimer's disease and its related dementia research. **Application Due Date:** March 24, 2020

[RFA-AT-20-004 \(UG3/UH3\)](#) – clinical trials optional

#### **HEAL Initiative: Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing**

The overall goal of this initiative is to support the "real world" assessment of health care strategies and clinical practices, and procedures in health care systems that may lead to improved pain management along with a reduction in unnecessary opioid prescribing. Awards made under this FOA will initially support a one-year, milestone-driven, planning phase (UG3), with possible transition to an implementation phase (UH3) of up to 4 years duration (5 years total for the two phases). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. **Application Due Date:** March 30, 2020



## October Due Dates

[RFA-AG-21-015 \(U19\)](#) – clinical trial not allowed

### **Network for Identification, Evaluation, and Tracking of Older Persons with Superior Cognitive Performance for Their Chronological Age**

This FOA invites applications to establish a network to identify, evaluate, track, and conduct research across multiple sites on older adults with superior cognitive performance for their age. The activity would support aggregation of sufficient numbers of these individuals to advance the field's understanding of factors that promote sustained cognitive health and those that are not of primary importance. Uniform identification and uniform data collection will allow the study of the behavioral, neurological, health, genetic, environmental, and lifestyle profiles that lead to sustained cognitive and brain function in advanced age. **Application Due Date:** October 1, 2020

[RFA-AG-21-011 \(R01\)](#) – clinical trial optional

### **Central and Peripheral Control of Balance in Older Adults**

This FOA is driven by the need to address a major gap in our understanding of how aging impacts the vestibular system, which, when impaired, contributes to balance problems and an increased risk of falls in older adults. Additionally, given that balance impairment can be attributed to a number of factors (e.g. sensory, motor, cognitive, psychological, and vascular function), understanding the contribution of age-related vestibular loss, and how this interacts with these factors, is critical for informing interventions and treatments for balance problems and falls in older adults.

**Application Due Date:** October 2, 2020

## Multiple Due Dates

[RFA-NS-20-008 \(R41/R42\)](#); [RFA-NS-20-010 \(R43/R44\)](#) - clinical trial required

[RFA-NS-20-009 \(R41/R42\)](#); [RFA-NS-20-011 \(R43/R44\)](#) – clinical trial not allowed

### **HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management**

These FOAs aim to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management. They are focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies. **Application Due Dates:** April 7, 2020, September 9, 2020, January 6, 2021, April 6, 2021, September 8, 2021, January 6, 2022, April 6, 2022, and September 8, 2022

[RFA-DA-19-019 \(R43/R44\)](#) – clinical trial optional

[RFA-DA-19-020 \(R41/R42\)](#) – clinical trial optional

### **America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis**

These FOAs invite applications from US small business concerns to develop technologies to provide science- and research-based solutions to the opioid emergency. **Application Due Dates:** April 9, 2020, September 8, 2020, April 9, 2021, September 8, 2021

[RFA-CA-20-004 \(R01\)](#); [RFA-CA-20-005 \(R21\)](#) – clinical trial optional

### **Research Answers to NCI's Provocative Questions**

These FOAs support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute Provocative Questions Initiative. The current issuance of the PQ Initiative includes an updated set of 9 PQs. Please refer to the funding announcements for the updated list.

**Application Due Dates:** April 30, 2020; November 17, 2020

[RFA-CA-20-019 \(R21\)](#) – **Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research**

[RFA-CA-20-020 \(R33\)](#) – **Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research**

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analyses during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

**Application Due Dates:** May 28, 2020; September 29, 2020

[RFA-CA-20-007 \(R21\)](#) – clinical trial optional

### **Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management**

This FOA invites applications for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. **Application Due Dates:** June 9, 2020; November 18, 2020

[RFA-CA-20-008](#) - Early Stage Development (U01)

[RFA-CA-20-009](#) – Advanced Development (U24)

[RFA-CA-20-010](#) – Sustained Support (U24)

**Informatics Technologies for Cancer Research and Management** – clinical trial optional

The central mission of these FOAs is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

[RFA-NS-19-043 \(K99/R00\)](#) – clinical trial not allowed; [RFA-NS-19-044 \(K99/R00\)](#) – independent clinical trial required

**BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity**

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space. **Application Due Dates:** June 10, 2020; October 9, 2020; February 10, 2021; June 9, 2021; October 6, 2021; February 10, 2022; June 8, 2022; October 11, 2022

[RFA-CA-19-034 \(P20\)](#) – clinical trial optional

**Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities**

The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. **Application Due Dates:** June 19, 2020, and October 18, 2020

[RFA-OD-20-008 \(K01\)](#) – clinical trial not allowed

[RFA-OD-20-011 \(K01\)](#) – clinical trial required

**Mentored Research Scientist Career Development Award in Tobacco Regulatory Research**

This award provides support and protected time (2-5 years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Candidates for the K01 award must have a research or health-professional doctoral degree.

**Application Due Dates:** July 8, 2020, February 08, 2021, October 08, 2021, July 8, 2022

[RFA-OD-20-009 \(K99/R00\)](#) – clinical trial not allowed

[RFA-OD-20-010 \(K99/R00\)](#) – clinical trial required

**Pathway to Independence Award in Tobacco Regulatory Research**

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers.

**Application Due Dates:** July 8, 2020, February 08, 2021, October 08, 2021, July 8, 2022

[RFA-OD-19-028 \(R01\)](#) – clinical trial optional

**Tobacco Regulatory Science**

This FOA supports biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).

**Application Due Dates:** July 17, 2020, February 13, 2021

[RFA-HL-19-024 \(R25\)](#) – clinical trial not allowed

**Short-Term Research Education Program to Increase Diversity in Health-Related Research**

The over-arching goal of this program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI.

**Application Due Dates:** September 10, 2020, February 26, 2021

[RFA-OD-19-022 \(R21\)](#) – clinical trial not allowed

### **Secondary Analyses of Existing Datasets of Tobacco Use and Health**

This FOA supports research proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

**Application Due Dates:** July 20, 2020, March 8, 2021

[RFA-OD-19-021 \(R21\)](#) – clinical trial not allowed

### **Maximizing the Scientific Value of Existing Biospecimen Collections: Scientific Opportunities for Exploratory Research**

This FOA invites applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. **Application Due Dates:** August 7, 2020, March 8, 2021

[RFA-ES-19-011 \(R21\)](#) – clinical trial not allowed

### **Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences**

This FOA supports novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.

**Application Due Dates:** Monthly due dates starting November 1, 2019; please refer to the RFA.

## **Program Announcements Reviewed by an Institute (PAR)**

[PAR-20-089 \(U24\)](#) – clinical trials not allowed

### **Biomedical Data Repository**

This FOA supports biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. **Application Due Dates:** September 25, 2020; January 25, 2021; September 24, 2021; January 25, 2022; September 26, 2022; January 25, 2023

[PAR-20-077 \(P01\)](#) – clinical trial optional

### **National Cancer Institute Program Project Applications**

NCI invites applications that address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

**Application Due Dates:** Standard dates apply; **Expiration Date:** May 8, 2023

[PAR-20-095 \(R25\)](#) – independent clinical trial not allowed

### **Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists**

More healthcare providers are needed to care for the growing population of older Americans. A variety of programs sponsored by the NIH, academic institutions, foundations, and other sources offer geriatrics- and aging-related research training. However, there is a need to develop robust multi-disciplinary research education resources that can be implemented in such training programs.

**Application Due Dates:** Standard dates apply; **Expiration Date:** January 26, 2023

[PAR-20-099 \(U24\)](#) – clinical trial not allowed

### **Harmonization of Alzheimer's Disease and Related Dementias (AD/ADRD) Genetic, Epidemiologic, and Clinical Data to Enhance Therapeutic Target Discovery**

NIA invites applications specific to infrastructure that will support, under a single cooperative agreement (U24), phenotypic data harmonization on subjects with Alzheimer's Disease Sequencing Project (ADSP) genetic and genomic data. The FOA will fund a single vanguard network of researchers with expertise in genetics, epidemiology, and clinical specialties who will work with the ADSP and with study cohort leads on data harmonization efforts to optimize the ability to identify well-targeted therapeutic approaches for Alzheimer's disease and related dementias (AD/ADRD).

**Application Due Dates:** Standard dates apply; **Expiration Date:** January 26, 2023

## ADMINISTRATION FOR COMMUNITY LIVING

### Disability and Rehabilitation Research Projects (DRRP) Programs

The purpose of NIDILRR's DRRP Program is to improve the effectiveness of services authorized under the Rehabilitation Act by generating new knowledge, or developing methods, procedures, and rehabilitation techniques that advance a wide range of independent living, employment, and health and function outcomes for individuals with disabilities, especially individuals with the most significant disabilities. **Application Due Dates for all listed below:** March 23, 2020

#### [HHS-2020-ACL-NIDILRR-DPKT-0381](#) - Projects for Translating the Findings and Products of Disability and Rehabilitation Research and Development into Practice

Applications submitted under this priority must promote the use or adoption of findings or products from NIDILRR-sponsored research or development projects. Projects are five years maximum and up to \$200,000.

### Community Living and Participation

#### [HHS-2020-ACL-NIDILRR-DPCP-0382](#) – Research

#### [HHS-2020-ACL-NIDILRR-DPCP-0383](#) – Development

NIDILRR will support innovative and well-designed applications that fall under one or more of the community living and participation priority areas. Projects are five years maximum and up to \$500,000.

### Health and Function

#### [HHS-2020-ACL-NIDILRR-DPHF-0384](#) – Research

#### [HHS-2020-ACL-NIDILRR-DPHF-0385](#) - Development

The application must contribute to the outcome of maximizing the health and function outcomes of individuals with disabilities. Projects are five years maximum and up to \$500,000.

#### [HHS-2020-ACL-NIDILRR-DPGE-0401](#) – Research on Healthcare Policy and Disability

This program seeks to generate new knowledge about the effect of evolving healthcare policies on access to health care services, community living or employment outcomes for people with disabilities. The application due date for this DRRP is **April 20, 2020**.

## FOUNDATION FUNDING OPPORTUNITIES

### American Cancer Society

The American Cancer Society has identified research addressing cancer health equity and health disparities as a priority within the [Cancer Prevention and Control Research Program](#). This includes research: 1. to understand, identify, and/or define modifiable or unjust factors that contribute to or sustain inequity (e.g., resources, access to care, behaviors, quality of care); and 2. that leads to a sustained reduction in disparities and/or equitable outcomes in cancer. Applications may use one of the following mechanisms:

#### [Research Scholar Grant](#)

For this program, applicants may be at any career stage. Awards may be up to 5 years with a maximum budget of \$400,000/year for direct costs. **Application Due Date:** April 1, 2020

#### [Postdoctoral Fellowship](#)

Applicants who are within 3 years of receiving a doctoral degree may apply for initial funding to start training for an independent career. Awards may be for 3 years with newly increased progressive stipends of \$52,000, \$54,000, and \$56,000/year. Applicants must be US citizens or permanent residents. **Application Due Date:** April 1, 2020

### *Individual Actions for Sustainability*

#### **Recycle more**

You can save 2,400 pounds of carbon dioxide per year by recycling just half of your household waste.

